LA JOLLA PHARMACEUTICAL COMPANY (NASDAQ:LJPC) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Item 5.02
LA JOLLA PHARMACEUTICAL COMPANY (NASDAQ:LJPC) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
On November 23, 2019, George Tidmarsh, M.D., Ph.D. resigned as the President and Chief Executive Officer of La Jolla Pharmaceutical Company (the “Company”) and as a member of the Company’s Board of Directors (the “Board”). Also, on November 23, 2019, Jennifer Carver resigned as the Company’s Chief Operating Officer.
Dr. Tidmarsh had served as the Company’s “principal executive officer,” as such term is defined under the Securities Exchange Act of 1934, as amended. Following Dr. Tidmarsh’s resignation, Dennis Mulroy, the Company’s Chief Financial Officer, was appointed to serve as the Company’s “principal executive officer,” pending further action from the Board.
Item 8.01. Other Events.
On November 25, 2019, the Company issued a press release regarding its intent to reassess continued development of LJPC-401 (synthetic human hepcidin) based on recent mixed clinical results. A copy of this press release is filed herewith as Exhibit 99.1 and is incorporated herein by reference.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
LA JOLLA PHARMACEUTICAL CO Exhibit
EX-99.1 2 exhibit-pr25nov19.htm EXHIBIT 99.1 Exhibit Exhibit 99.1La Jolla to Reassess Continued Development of LJPC-401 Based on Recent Clinical ResultsSAN DIEGO,…
To view the full exhibit click
EX-99.1 2 exhibit-pr25nov19.htm EXHIBIT 99.1 Exhibit Exhibit 99.1La Jolla to Reassess Continued Development of LJPC-401 Based on Recent Clinical ResultsSAN DIEGO,…
To view the full exhibit click
hereAbout LA JOLLA PHARMACEUTICAL COMPANY (NASDAQ:LJPC)
La Jolla Pharmaceutical Company is a biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapies to improve outcomes in patients suffering from life-threatening diseases. It is engaged in the research, development and commercialization of its technologies and drug candidates for pharmaceutical products. Its product candidates in development include LJPC-501, LJPC-401, LJPC-30Sa and LJPC-30Sb. The Company is developing LJPC-501 for the treatment of catecholamine-resistant hypotension (CRH). The Company is developing LJPC-401 for the treatment of iron overload, which occurs as a result of diseases, such as hereditary hemochromatosis, beta thalassemia, sickle cell disease and myelodysplastic syndrome. It is developing LJPC-30Sa and LJPC-30Sb not only for the treatment of serious bacterial infections but also for the potential treatment of rare genetic disorders, such as cystic fibrosis and Duchenne muscular dystrophy.
